Richards, Merrill & Peterson’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$485K Buy
1,151
+15
+1% +$5.98K 0.15% 125
2026
Q2
$411K Hold
1,136
– – 0.13% 135
2026
Q1
$400K Sell
1,136
-30
-3% -$10.7K 0.15% 131
2025
Q4
$382K Sell
1,166
-5
-0.4% -$1.59K 0.15% 133
2025
Q3
$331K Sell
1,171
-5
-0.4% -$1.45K 0.14% 130
2025
Q2
$328K Buy
1,176
+22
+2% +$6.23K 0.16% 131
2025
Q1
$360K Sell
1,154
-90
-7% -$26.6K 0.19% 111
2024
Q4
$324K Buy
+1,244
New +$369K 0.17% 116

Other funds holding AMGN

Richards, Merrill & Peterson's AMGN Position: Q3 2026 in Review

Richards, Merrill & Peterson increased its Amgen (AMGN) stake by 1.3% in Q3 2026, buying an estimated $5.98K and bringing the position to 1,151 shares worth $485K. The position accounts for 0.15% of the portfolio, ranked #125.

Richards, Merrill & Peterson first reported a position in AMGN in Q4 2024 and has held it in 8 quarters since. 3,253 funds tracked by Wall St. Rank hold AMGN as of Q3 2026.

  • Richards, Merrill & Peterson held 1,151 shares of Amgen worth $485K as of Q3 2026.
  • Richards, Merrill & Peterson bought 15 Amgen shares in Q3 2026, an estimated $5.98K.
  • Amgen made up 0.15% of Richards, Merrill & Peterson's portfolio in Q3 2026, its #125 holding.
  • Richards, Merrill & Peterson first reported a position in Amgen in Q4 2024 and has held it in 8 quarters since.
  • 3,253 funds tracked by Wall St. Rank held Amgen as of Q3 2026.

Based on Richards, Merrill & Peterson's 13F filing for Q3 2026, filed 19 Oct 2026.